Max is a litigation associate. His practice is focused on mass torts, and also includes class actions and whistleblower matters.
Max was a central player in the In re 3M litigation from its inception, and served on multiple trial teams that recovered seven-figure verdicts for injured servicemembers in that MDL, one of the largest mass torts in history. Max helped manage corporate discovery in litigation against the Norfolk Southern Railway company in connection with the February 2023 chemical train derailment, including taking the deposition of Norfolk Southern’s Director of Environmental Protection.
Max is presently a core member of the In re GLP1-RAs team, pursuing claims on behalf of users of Ozempic, Mounjaro, and similar drugs, against Novo Nordisk and Eli Lilly relating to their failure to warn of risks of injuries caused by their weight loss drugs. His other current matters include the In re Allergan litigation, relating to unreasonably dangerous breast implants. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Prior to joining Seeger Weiss, Max was an associate at Milbank Tweed in New York, primarily representing defendants in the financial services industry in the context of complex commercial disputes, government investigations, and class actions. During his time as a law student, Max was a research assistant to Professor Arthur R. Miller, providing revisions and updates to Federal Practice and Procedure, one of the most frequently cited treatises in federal court practice in the United States.
